Could a diabetes drug ease chest pain in women with hidden heart disease?

NCT ID NCT06600178

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called Brezavvy (an SGLT2 inhibitor) can improve blood flow in the tiny vessels of the heart and reduce chest pain in women who have angina but no blocked major arteries. 150 women will take either the drug or a placebo for 12 weeks and undergo heart scans and questionnaires. The goal is to see if this treatment can help manage a condition that often goes undiagnosed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Brezavvy (SGLT2 inhibitor)
What this could lead to
If successful, this could point toward a new treatment option for women with chest pain caused by small heart vessel problems, improving their quality of life.
What could go wrong
This is an early Phase 1 trial with only 150 participants, so results may not apply to everyone. The drug may not improve symptoms or could have side effects not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGINA PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UVA Health

    RECRUITING

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.